



PATENT  
Customer No. 22,852  
Attorney Docket No. 09487.0003-00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	)	
<b>John DEVANE</b>	)	Confirmation No. 6571
	)	
Application No. 10/798,421	)	Group Art Unit: 1614
	)	
Filed: March 12, 2004	)	Examiner: Phyllis Spivack
	)	
For: TREATMENT OF INTESTINAL	)	
CONDITIONS WITH N-2,3,3-	)	
TETRAMETHYLBICYCLO[2.2.1]H	)	
EPTAN-2-2AMINE	)	

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**SUBSTITUTE SPECIFICATION UNDER 37 CFR §1.125(b)**

Applicant submits the enclosed "Marked-up Substitute Specification" and "Clean Copy of the Substitute Specification," and requests that the Examiner replace the originally filed specification with the enclosed substitute specification.

Specifically, the specification at paragraph [012] correctly identifies mecamlamine as being *N*-2,3,3-tetramethylbicyclo[2.2.1]heptan-2-amine. Moreover, it is well known in the art that the chemical name for mecamlamine is *N*-2,3,3-tetramethylbicyclo[2.2.1]heptan-2-amine. However, there are instances in the specification as well as in the pending claims (which are being corrected with the Reply to Office Action submitted concurrently herewith) where mecamlamine is referred to as being *N*-2,2,3-tetramethylbicyclo-[2.1.1]heptan-2-amine

instead of *N*-2,3,3-tetramethylbicyclo[2.2.1]heptan-2-amine. The substitute specification corrects those typographical errors where mecamylamine is referred to as being *N*-2,2,3-tetramethylbicyclo-[2.1.1]heptan-2-amine instead of *N*-2,3,3-tetramethylbicyclo[2.2.1]heptan-2-amine.


Accordingly, no new matter has been added to the substitute specification.

Please grant any extensions of time required to enter this response and charge any additional required fees to Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,  
GARRETT & DUNNER, L.L.P.

Dated: May 7, 2007

By:   
Adriana L. Burgy  
Reg. No. 48,564